Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE).
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 36825498.
- Also identified by DOI 10.1093/cid/ciad107 and PMC identifier 10474926.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Over 2-years of follow-up, integrase strand transfer inhibitor (INSTI)-use was associated with weight gain among those on an INSTI <2 years at entry (+0.27 kg/m2/year; 95% confidence interval [CI], .22 to .33 vs +0.17 kg/m2/year; 95% CI, .12 to .23; P = .01), but not those on an entry INSTI >2 years.
Medical subject headings
- HIV Infections
- HIV Integrase Inhibitors
- HIV-1
- HIV Integrase